Related references
Note: Only part of the references are listed.Oxaliplatin plus S-1 with intraperitoneal paclitaxel for the treatment of Chinese advanced gastric cancer with peritoneal metastases
Min Shi et al.
BMC CANCER (2021)
Considerations in the development and validation of real-time quantitative polymerase chain reaction and its application in regulated bioanalysis to characterize the cellular kinetics of CAR-T products in clinical studies
Tong-yuan Yang et al.
BIOANALYSIS (2021)
CAR T cells in solid tumors: challenges and opportunities
Faroogh Marofi et al.
STEM CELL RESEARCH & THERAPY (2021)
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma
U. Sahin et al.
ANNALS OF ONCOLOGY (2021)
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C. Munshi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CAR-T Flow Cytometry, NAb Assay Harmonization and ELISpot Validation (Part 3-Recommendations on Immunogenicity Assay Strategies, NAb Assays, Biosimilars and FDA/EMA Immunogenicity Guidance/Guideline, Gene & Cell Therapy and Vaccine Assays)
Bart Corsaro et al.
BIOANALYSIS (2021)
The Burden of Peritoneal Metastases from Gastric Cancer: A Systematic Review on the Incidence, Risk Factors and Survival
Anouk Rijken et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia
Talha Badar et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2020)
Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial
Yang Liu et al.
CYTOTHERAPY (2020)
Engineering CAR-T Cells for Next-Generation Cancer Therapy
Mihe Hong et al.
CANCER CELL (2020)
Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer
Hua Jiang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer
Hua Jiang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Phase I trial of Claudin 18.2-specific chimeric antigen receptor T cells for advanced gastric and pancreatic adenocarcinoma.
Xianbao Zhan et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study
O. Tuereci et al.
ANNALS OF ONCOLOGY (2019)
Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies
Jiali Cheng et al.
FRONTIERS IN ONCOLOGY (2019)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium
Michael D. Jain et al.
BLOOD (2019)
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
Xianjie Jiang et al.
MOLECULAR CANCER (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers
Kaichao Feng et al.
PROTEIN & CELL (2018)
Lauren Histologic Type Is the Most Important Factor Associated With Pattern of Recurrence Following Resection of Gastric Adenocarcinoma
Jun H. Lee et al.
ANNALS OF SURGERY (2018)
CAR T-Cell Therapy in Large B-Cell Lymphoma
Alfonso Quintas-Cardama
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial
Charles S. Fuchs et al.
JAMA ONCOLOGY (2018)
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial
Kohei Shitara et al.
LANCET ONCOLOGY (2018)
Phase I Study of Chimeric Antigen Receptor-Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers
Yelei Guo et al.
CLINICAL CANCER RESEARCH (2018)
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Yoon-Koo Kang et al.
LANCET (2017)
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
Frederick L. Locke et al.
MOLECULAR THERAPY (2017)
Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge
Simon Pernot et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
PD-1 induction through TCR activation is partially regulated by endogenous TGF-β
Raja Rekik et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2015)
Standardization of Diagnostic Immunohistochemistry Literature Review and Geisinger Experience
Fan Lin et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2014)
Principles of Analytic Validation of Immunohistochemical Assays Guideline From the College of American Pathologists Pathology and Laboratory Quality Center
Patrick L. Fitzgibbons et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2014)
Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer
Yasutsuna Sasaki et al.
CANCER SCIENCE (2014)
Stromal disrupting effects of nab-paclitaxel in pancreatic cancer
R. Alvarez et al.
BRITISH JOURNAL OF CANCER (2013)
Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner
Tillmann Michels et al.
JOURNAL OF IMMUNOTOXICOLOGY (2012)
Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
Daniel D. Von Hoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
PD-1 and its ligands in T-cell immunity
Mary E. Keir et al.
CURRENT OPINION IN IMMUNOLOGY (2007)
Intraperitoneal antineoplastic drug delivery: rationale and results
M Markman
LANCET ONCOLOGY (2003)
Share Paper
